2 recruiting, 1 active not recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Beijing Scitech-Mq Pharmaceuticals Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer ST-1898 tablets - Differentiated Thyroid Carcinoma | Phase 2 | Recruiting | Beijing Scitech-Mq Pharmaceuticals Limited | 60 | 2023-11-15 | 2025-08-24 |
| A Study of ST-1898 for Unresectable or Metastatic Melanoma ST-1898 tablets - Unresectable or Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Beijing Scitech-Mq Pharmaceuticals Limited | 64 | 2023-11-07 | 2025-08-24 |
| Study of ST-1898 in Advanced Renal Cell Carcinoma ST-1898 tablets - Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Beijing Scitech-Mq Pharmaceuticals Limited | 90 | 2023-02-07 | 2025-08-24 |
Carcinoma, Renal Cell (1) · Melanoma (1)
3-(3'-adamantan-1-yl-4'-methoxybiphenyl-4-yl)-2-propenoic acid (3)
China (3)
Jun Guo, Ph D (1) · Yansong Lin, Ph D (1)